Deriving new drugs from thalidomide.
George W. Muller and David I. Stirling, chemists at Celgene Corp. in Warren, N.J., reengineered thalidomide to create a new series of therapeutic agents.
The researchers have designed the drugs, they say, to regulate the body's production of tumor necrosis factor alpha. This protein plays a key role in inflammatory and immunological disorders such as rheumatoid arthritis, lupus, inflammatory bowel disease, and leprosy.
Scientists at Johns Hopkins University in Baltimore are currently studying several of these new Celgene agents for treatment of graft-versus-host disease, which often follows bone marrow transplants, Muller adds.
In designing these new molecules, Muller and Stirling said, they improved the potency of the portion of thalidomide exhibiting medicinal properties and removed the segment causing birth defects.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Chemistry; new thalidomide agents regulate body's ability to produce tumor necrosis factor alpha, a major contributor to inflammatory and immunological disorders|
|Article Type:||Brief Article|
|Date:||Sep 9, 1995|
|Previous Article:||Drugs target RNA to kill tumors ... and block HIV.|
|Next Article:||Electron beam cleans dirty water.|